Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc1, -1% USD), as…
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
Novartis delivered sales growth in Q2 and further advanced
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
Novartis delivered sales growth in Q2 and further advanced
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc1, +3% USD), with…
Novartis delpacibart braxlosiran (del-brax) Phase I/II
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction…
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to…
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN…
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1
Ad hoc announcement pursuant to Art. 53 LR Net sales grew +15% (cc1, +12% USD) with core operating…
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition trial met its primary endpoint showing…
Novartis appoints Mukul Mehta as Chief Financial Officer, as Harry Kirsch retires after 22 years with the company
Ad hoc announcement pursuant to Art. 53 LR Mukul Mehta, currently Head of Business Planning and Analysis (BPA),…
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +7% (cc1, +8% USD) and core…